Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza vaccination immunogenicity and tolerability in patients with systemic or autoimmune disease
2009-016086-28Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2009
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Mutagrip and Influenza A (H1N1) vaccine in influenza, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Seroprotection rate after vaccination. Started Oct 2009; status: active.
02
Drugs
MutagripInfluenza A (H1N1) vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2009-016086-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016086-28.